Home RSS

Seattle Genetics cancer drug to get faster review

Forbes 03/30/2009 14:27
Seattle Genetics cancer drug to get faster review - cancer - drug


The Food and Drug Administration will conduct a faster review of Seattle Genetics Inc.'s cancer drug candidate SGN-35, the biotechnology company said Monday.



Seattle Geneticssaid the FDA granted fast track status to SGN-35 as a treatment for Hodgkin's disease, meaning it will conduct a six-month review of the drug instead of the usual 10 months.

The company plans to ask for FDA approval of SGN-35 in 2011, and hopes to launch the drug the following year.

Source



Add your comment
  Anonymous comment
Nickname:
Password:
  Remember me on this computer

Title:
Send me by email any answer to my comment
Send me by email every new comment to this article